Ask AI
Treat to Target in CD
Interactive Case Challenge 1: Treat-to-Target in Crohn’s Disease 

Released: March 17, 2025

Activity

Progress
1
Course Completed

  1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583. 
  2. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153:827-834. 
  3. Gordon H, Minozzi S, Kopylov U, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2024;18:1531-1555. 
  4. Ferrante M, D'Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404:2423-2436.. 
  5. Vuyyuru SK, Solitano V, Hogan M, et al. Efficacy and safety of IL-12/23 and IL-23 inhibitors for Crohn’s disease: systematic review and meta-analysis. Dig Dis Sci. 2023;68:3702-3713. 
  6. Mirikizumab [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
  7. Maaser C, Petersen F, Helwig U, et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut. 2020;69(9):1629-1636.
  8. Stoker AMH, Logghe L, van der Ende-van Loon MCM, et al. Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clin Exp Med. 2023;23:2789-2797.